Results 1 to 10 of about 22,784 (283)

Angioedema associated with dipeptidyl peptidase-IV inhibitors. [PDF]

Clin Mol Allergy, 2021
Abstract Background Dipeptidyl peptidase-IV (DPP-IV) inhibitors, also known as gliptins, are a class of oral antidiabetic agents. Postmarketing reports have documented the occurrence of angioedema in patients treated with gliptins and it was found that these drugs increased the risk of angioedema in patients concurrently
Cassano N, Nettis E, Di Leo E, Ambrogio F, Vena GA, Foti C.   +5 more
europepmc   +5 more sources

Identification of potential dipeptidyl peptidase IV inhibitors from the ConMedNP library by virtual screening, and molecular dynamics methods. [PDF]

Heliyon
In this study, we screened novel dipeptidyl peptidase IV (DPP4) inhibitors from the ConMedNP library consisting of 3507 molecules. Interestingly, molecular docking, ADMET, and the anti-diabetic activity predictions suggest that three molecules, namely ...
Tsahnang Fofack HM, Mbah Bake M, Petry S, Ateba BA, Amoa Onguéné P, Mohammad-Salim H, Ntie-Kang F, Mbaze LM, Vakal S, Kenfack CA.   +9 more
europepmc   +2 more sources

Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors [PDF]

Diabetologia, 2012
To the Editor: The position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recently published an updated algorithm for the initiation and adjustment of therapy for the management of hyperglycaemia in type 2 diabetes [1].
A J Scheen
openaire   +3 more sources

Dipeptidyl peptidase IV inhibitors derived from a mangrove flora <i>Rhizophora mucronata</i>: An <i>in silico</i> approach

Bangladesh Journal of Pharmacology, 2012
Dipeptidyl peptidase IV (DPP IV) is responsible for conversion of glucose tolerance (GLP-1), into inactive form. The inhibition of DPP IV would be beneficial in the treatment of diabetes mellitus.
Gurudeeban Selvaraj, K. Satyavani, T. Ramanathan, P Ravikumar   +3 more
openalex   +4 more sources

Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2006
A series of xanthine mimetics containing 5,5 and 5,6 heterocycle fused imidazoles were synthesized as dipeptidyl peptidase IV inhibitors. Compound 7 is potent (h-DPPIV K(i)=2nM) and exhibits excellent selectivity and no species specificity against rat and human enzymes.
Ravi, Kurukulasuriya, Jeffrey J, Rohde, Bruce G, Szczepankiewicz, Fatima, Basha, Chunqui, Lai, Hwan-Soo, Jae, Martin, Winn, Kent D, Stewart, Kenton L, Longenecker, Thomas W, Lubben, Stephen J, Ballaron, Hing L, Sham, Thomas W, von Geldern   +12 more
openaire   +3 more sources

4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2004
Substituted 4-amino cyclohexylglycine analogues were evaluated for DP-IV inhibitory properties. Bis-sulfonamide 15e was an extremely potent 2.6 nM inhibitor of the enzyme with excellent selectivity over all counterscreens. 2,4-difluorobenzenesulfonamide 15b and 1-naphthyl amide 16b, however, combined an acceptable in vitro profile with good ...
Emma R, Parmee, Jiafang, He, Anthony, Mastracchio, Scott D, Edmondson, Larry, Colwell, George, Eiermann, William P, Feeney, Bahanu, Habulihaz, Huaibing, He, Ruth, Kilburn, Barbara, Leiting, Kathryn, Lyons, Frank, Marsilio, Reshma A, Patel, Aleksandr, Petrov, Jerry, Di Salvo, Joseph K, Wu, Nancy A, Thornberry, Ann E, Weber   +18 more
openaire   +3 more sources

Pyrazolidine Derivatives with Heteroaryl Urea as Dipeptidyl Peptidase IV Inhibitors

Chemical and Pharmaceutical Bulletin, 2005
In the continuation of efforts to modify the structure of our novel DP-IV inhibitors, a series of pyrazolidine derivatives with heteroaryl urea was synthesized and evaluated for their ability to inhibit dipeptidyl peptidase IV (DP-IV).
Jin Hee, Ahn, Sun Ho, Jung, Jin Ah, Kim, Seog Beom, Song, Soon Ji, Kwon, Kwang Rok, Kim, Sang Dal, Rhee, Sung-Dae, Park, Jae Mok, Lee, Sung Soo, Kim, Hyae Gyeong, Cheon   +10 more
openaire   +4 more sources

Potent and selective proline derived dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2004
In-house screening of the Merck sample collection identified proline derived homophenylalanine 3 as a DPP-IV inhibitor with modest potency (DPP-IV IC50=1.9 microM). Optimization of 3 led to compound 37, which is among the most potent and selective DPP-IV inhibitors discovered to date.
Scott D, Edmondson, Anthony, Mastracchio, Maria, Beconi, Lawrence F, Colwell, Bahanu, Habulihaz, Huaibing, He, Sanjeev, Kumar, Barbara, Leiting, Kathryn A, Lyons, Ann, Mao, Frank, Marsilio, Reshma A, Patel, Joseph K, Wu, Lan, Zhu, Nancy A, Thornberry, Ann E, Weber, Emma R, Parmee   +16 more
openaire   +3 more sources

Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid [PDF]

Dermatology, 2017
Schaffer, Clara, Buclin, Thierry, Jornayvaz, François, Cazzaniga, Simone, Borradori, Luca, Gilliet, Michel, Feldmeyer, Laurence   +6 more
openaire   +5 more sources

Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]

, 2014
The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen, AA Riedel, AI Adler, AJ Garber, AR Saltiel, BD Green, BI Yan, BM Scirica, Brian C. Y. Fong, C Castell, C Levetan, Carmen K. M. Fan, CC Cowie, CE Van Dijk, CJ Bailey, CN Chan, Daisy D. X. Zhang, DC Simonson, DR Owens, DS Schade, FA Guisasola, François Blachier, Harry H. X. Wang, J Lopatynski, J Mest H, J Rosenstock, K Kaku, Kirin Q. L. Liu, L Groop, M Kobayashi, M Stumvoll, M Takihata, Mandy W. M. Kwan, Martin C. S. Wong, MC Wong, N Inagaki, N Inagaki, O Mosenzon, R Kawamori, RA DeFronzo, S Aronoff, S Clement, SE Kahn, SE Kahn, SE Nissen, Shannon T. S. Li, Sian M. Griffiths, Sky W. M. Chan, SL Zhang, T Kadowaki, V Mohan, W Gareth, W Yang, WB White, Y Guan, Y Seino, Y Seino, YG Kim, Z Zeng   +58 more
core   +10 more sources